Figure 4.
Effect of compound 1 on the expression of PPARγ and PPARγ-target gene products in MCF-7 cells. (A) Upper panel, the expression of PPARγ after treatment with compound 1 for 48 h in MCF-7 cells. Lower panel, fold change of PPARγ/β-actin in compound 1-treated MCF-7 cells compared with DMSO control (n = 3); (B) Western blot analysis of compound 1 on the phosphorylation and/or expression of cyclin D1, CDK6, Bcl-2, ERK, and p38. MCF-7 cells were exposed to compound 1 at indicated concentrations for 48 h; (C) Relative protein expression of cyclin D1/β-actin, CDK6/β-actin, Bcl-2/β-actin, p-ERK/β-actin, ERK/β-actin, p38/β-actin and p-p38/β-actin in compound 1-treated MCF-7 cells compared with DMSO control (n = 3).
